Dental: Osteoporosis: Implications for the Oral Healthcare Provider, 2nd edition

29.95
Online
Elective
Please select your state to enroll in this course
About the Course
This course will address current concepts regarding links between oral health and osteoporosis, discuss the impact on oral health of pharmacotherapies used in the treatment of osteoporosis, and outline steps to mitigate the impact on oral health of drugs commonly used to treat osteoporosis. This intermediate-level course is intended for dental professionals involved in the treatment of patients with and at risk for low bone mass and osteoporosis.

Both periodontal disease and osteoporosis are serious public health concerns in the United States. There is evidence that osteoporosis, and the characteristic loss of bone mass, is associated with periodontal disease and tooth loss. To optimize the oral health care of patients with osteoporosis and those who are at risk for the condition, dentists and other members of the dental team should be aware of the clinical (and possibly pathophysiologic) link between these increasingly common conditions.

Course Objectives
  1. Describe the etiology and prevalence of osteoporosis.
  2. Discuss the putative association between osteoporosis and periodontal disease.
  3. Explain the pharmacological treatment of osteoporosis.
  4. Describe the oral health implications of medically related jaw necrosis.
  5. Identify evidence-based guidelines for the management of bisphosphonate-treated patients.
  6. Describe the importance of screening for osteoporosis.

About the Author
John F. Kross, DMD, MSc, received his doctor of dental medicine degree from Temple University School of Dentistry in Philadelphia, Pennsylvania. He completed a fellowship at Temple University Hospital in oral oncology and received a hospital appointment to the Department of Dentistry at the Medical Centers of Delaware (now the Christiana Health Care System). His professional training and experience includes practicing general dentistry in Wilmington, Delaware, and New London, Pennsylvania, as well as instructing students in oral pathology at Delaware Technical Community College. He has displayed a long-term commitment to contributing to continuing dental education and has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics. Dr. Kross has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics. He is cofounder of Dental Regulatory Associates, a company specializing in U.S. Food and Drug Administration approval of dental drugs and devices.


AGD Subject Code: 730
Want Unlimited CE? Become a Member

Osteoporosis: Implications for the Oral Healthcare Provider, 2nd edition

29.95
About the Course
This course will address current concepts regarding links between oral health and osteoporosis, discuss the impact on oral health of pharmacotherapies used in the treatment of osteoporosis, and outline steps to mitigate the impact on oral health of drugs commonly used to treat osteoporosis. This intermediate-level course is intended for dental professionals involved in the treatment of patients with and at risk for low bone mass and osteoporosis.

Both periodontal disease and osteoporosis are serious public health concerns in the United States. There is evidence that osteoporosis, and the characteristic loss of bone mass, is associated with periodontal disease and tooth loss. To optimize the oral health care of patients with osteoporosis and those who are at risk for the condition, dentists and other members of the dental team should be aware of the clinical (and possibly pathophysiologic) link between these increasingly common conditions.

Course Objectives
  1. Describe the etiology and prevalence of osteoporosis.
  2. Discuss the putative association between osteoporosis and periodontal disease.
  3. Explain the pharmacological treatment of osteoporosis.
  4. Describe the oral health implications of medically related jaw necrosis.
  5. Identify evidence-based guidelines for the management of bisphosphonate-treated patients.
  6. Describe the importance of screening for osteoporosis.

About the Author
John F. Kross, DMD, MSc, received his doctor of dental medicine degree from Temple University School of Dentistry in Philadelphia, Pennsylvania. He completed a fellowship at Temple University Hospital in oral oncology and received a hospital appointment to the Department of Dentistry at the Medical Centers of Delaware (now the Christiana Health Care System). His professional training and experience includes practicing general dentistry in Wilmington, Delaware, and New London, Pennsylvania, as well as instructing students in oral pathology at Delaware Technical Community College. He has displayed a long-term commitment to contributing to continuing dental education and has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics. Dr. Kross has received numerous academic awards for his work in oral surgery, fixed partial prosthodontics, periodontics, and endodontics. He is cofounder of Dental Regulatory Associates, a company specializing in U.S. Food and Drug Administration approval of dental drugs and devices.


AGD Subject Code: 730